Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of “Hold” by Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been given an average recommendation of “Hold” by the eight brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $5.25.

Separately, Wells Fargo & Company upped their target price on Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research report on Monday, December 15th.

Maravai LifeSciences Price Performance

MRVI opened at $2.96 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.29 and a quick ratio of 4.56. The stock has a 50-day moving average price of $3.52 and a 200-day moving average price of $3.14. The firm has a market cap of $756.90 million, a PE ratio of -3.52 and a beta of 0.39. Maravai LifeSciences has a 1 year low of $1.66 and a 1 year high of $4.40.

Insider Activity

In other news, Director Gregory T. Lucier purchased 51,472 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were bought at an average price of $3.70 per share, for a total transaction of $190,446.40. Following the completion of the transaction, the director owned 106,595 shares in the company, valued at $394,401.50. This represents a 93.38% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 2.11% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Maravai LifeSciences

A number of large investors have recently modified their holdings of the business. Monaco Asset Management SAM grew its holdings in shares of Maravai LifeSciences by 315.0% in the third quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock valued at $10,494,000 after purchasing an additional 2,775,372 shares during the period. Tejara Capital Ltd grew its stake in shares of Maravai LifeSciences by 257.8% in the 2nd quarter. Tejara Capital Ltd now owns 1,941,449 shares of the company’s stock valued at $4,679,000 after buying an additional 1,398,900 shares during the period. First Eagle Investment Management LLC increased its holdings in shares of Maravai LifeSciences by 299.0% during the 4th quarter. First Eagle Investment Management LLC now owns 1,799,336 shares of the company’s stock worth $5,848,000 after buying an additional 1,348,405 shares during the last quarter. First Pacific Advisors LP purchased a new position in Maravai LifeSciences in the second quarter worth approximately $1,787,000. Finally, Marshall Wace LLP raised its position in Maravai LifeSciences by 52.3% in the fourth quarter. Marshall Wace LLP now owns 2,000,278 shares of the company’s stock valued at $6,501,000 after purchasing an additional 687,253 shares during the period. Hedge funds and other institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.